Stanford scientists rewire lymphoma protein to kill cancer cells in mice
Stanford Medicine researchers developed a molecule that turns a B-cell lymphoma driver against tumors, eliminating them in mice within 11 days on October 7, 2026.
New molecular strategy targets cancer
Researchers at Stanford Medicine created a two-part molecule designed to fight cancer using its own driving force. Instead of blocking tumor growth, this compound connects a cancer-promoting protein to another that triggers cell death. The experimental treatment was administered twice daily to subjects in laboratory studies.
Rapid results seen in lab tests
Aggressive human lymphoma tumors disappeared completely from mice after just eleven days of the new therapy. This approach activates the built-in self-destruct machinery inside the cancer cells rather than simply shutting down their growth signals. The team notes that further testing is required before this method can be used on patients.
Potential uses beyond lymphoma
The scientists believe this molecular rewiring technique might help treat other types of cancer in the future. They also suggest it could have applications for addressing certain autoimmune diseases that rely on similar protein mechanisms. Gerald Crabtree stated the goal is to fight cancer by taking its driving force and redirecting it.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.